Epidemic Keratoconjunctivitis Treatment Market
Market Insights on Epidemic Keratoconjunctivitis Treatment covering sales outlook, demand forecast & up-to-date key trends
Epidemic Keratoconjunctivitis Treatment Market by Drug Class, Route of Administration, Distribution Channel & Region Forecast from 2023 to 2033
Epidemic Keratoconjunctivitis Treatment Market Snapshot (2023 to 2033)
The global epidemic keratoconjunctivitis treatment market is expected to garner a market value of US$ 500 million in 2023 and is expected to accumulate a market value of US$ 814.45 million by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for Epidemic Keratoconjunctivitis Treatment registered a CAGR of 4% in the historical period 2018 to 2022.
The epidemic keratoconjunctivitis treatment market is a segment of the healthcare industry that deals with the effective management of epidemic keratoconjunctivitis. The epidemic keratoconjunctivitis treatment market offers a range of products and services for its effective management and treatment such as antiviral or steroid eye drops, as well as proper hygiene measures to prevent the spread of the virus. Treatment for EKC typically involves symptom management and reducing the spread of the virus to others.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 500 million |
|
Anticipated Forecast Value (2033) |
US$ 814.45 million |
|
Projected Growth Rate (2023 to 2033) |
5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Epidemic Keratoconjunctivitis Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Epidemic Keratoconjunctivitis Treatment reflected a value CAGR of 4% during the historical period, 2018 to 2022.
According to the USA General Population Cross-sectional Study, 2018, around 16 to 49 million Americans have a dry eye disease, accounting for 5% to 15% of the total population. The increasing incidence of Epidemic Keratoconjunctivitis have been reported in schools, offices, and public areas, as well as in institutional settings such as nursing homes and military training facilities. Various factors have been impacting the prevalence of Epidemic Keratoconjunctivitis such as the level of hygiene, the presence of contaminated objects, and the susceptibility of the individual. EKC outbreaks are most common in crowded areas, such as schools, nursing homes, and military training facilities.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for Epidemic Keratoconjunctivitis Treatment. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Epidemic Keratoconjunctivitis Treatments is fuelling the market growth. Thus, the market for Epidemic Keratoconjunctivitis Treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of the Epidemic Keratoconjunctivitis Treatment Market?
Increased Prevalence of Epidemic Keratoconjunctivitis in Elderly Population to Push the Market Growth
The global market for epidemic keratoconjunctivitis treatment is primarily driven by the increasing prevalence of the disease, the development of new and effective treatment options, advancements in treatment technologies, development of new diagnostic technologies and the availability of more effective treatments. In addition, increased awareness of Epidemic Keratoconjunctivitis, especially amongst geriatric population which is at higher risk of Epidemic Keratoconjunctivitis, has led to a higher healthcare expenditure globally contributing to the growth of the market.
Furthermore, the prevalence of epidemic keratoconjunctivitis is high in low and middle-income countries, offering a significant market opportunity for companies to expand their product offerings. The prevalence of Epidemic Keratoconjunctivitis has increased in recent years due to factors such as increased international travel, urbanization, and the aging of the population, which is expected to drive demand for Epidemic Keratoconjunctivitis treatments.
Antiviral medications, Steroid Eye Drops, Proper Hygiene, Wearing Protective Eyewear are some of the effective measures of reducing the risk of Epidemic Keratoconjunctivitis and other eye infections.
Another factor driving the market is the increase in air pollution in many cities worldwide. A study published by the National Center for Biotechnology Information (NCBI) in 2016 found that the main causes of allergic conjunctivitis are air pollution and weather changes. This is because the conjunctiva is sensitive to environmental particles and has direct contact with the external environment. As a result, an increase in air pollution drives the growth of the global market.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Epidemic Keratoconjunctivitis Treatment Market?
Expensive Cost of Treatment to restrict Market Growth
The market is projected to get significantly affected by challenging factors such as limited availability and high cost of advanced Epidemic Keratoconjunctivitis Treatment options. Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, is expected to hinder the market growth.
Furthermore, poor healthcare infrastructure, especially in developing countries, can limit access to Epidemic Keratoconjunctivitis treatment and the availability of diagnostic and therapeutic options.
Region-Wise Insights
How is the Epidemic Keratoconjunctivitis Treatment Market Turning Out in the Asia Pacific Region?
Improvement in healthcare spending propelling growth of Epidemic Keratoconjunctivitis Treatment in Asia Pacific
The Asia Pacific is expected to exhibit the significant growth rate of all regions over the forecast period, with a revenue share of 25% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Epidemic Keratoconjunctivitis Treatment Market in the region. Asia Pacific is an emerging market due to the increase in point of care approach to health & care. Increasing number of hospitals in India and China makes a promising market for the market worldwide.
What are the Factors Boosting the Market for Epidemic Keratoconjunctivitis Treatment in North America?
Increasing Prevalence of EKC Shaping Landscape for Epidemic Keratoconjunctivitis Treatment in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region.
As per the National Library Medicine article published in February 2020, conjunctivitis affects more than 6 million people across the United States every year. Factors such as a large and aging population and increasing awareness about Epidemic Keratoconjunctivitis are leading to the growth of the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
By End-users, Which Segment is Likely to Account for a Significant Share?
Hospital Pharmacy to take the lead and drive market growth
According to the FMI analysis, Hospital pharmacy accounts for the largest market share. Hospital pharmacies have access to antiviral medications, such as acyclovir and trifluridine, which are essential for treating epidemic keratoconjunctivitis.
Furthermore, many hospital pharmacies are covered by insurance plans, which can help patients pay for the cost of their treatment, making it more accessible and affordable.
Startup Scenario
Key startups in the epidemic keratoconjunctivitis treatment market include-
- Ocuphire Pharma is a US-based start-up commercializing therapies for eye disorders. The start-up’s lead intravitreal formulation, APX2009, is undergoing preclinical development for the treatment of wet age-related macular degeneration (wAMD). The startup is also working on formulations to treat diabetic retinopathy (DR) and diabetic macular edema.
- South Korean start-up PinoTBio offers targeted therapies for ophthalmology and oncology. The startup’s proprietary technology modifies and configures nucleoside analogs to develop targeted therapeutic agents. PinotBio’s pipeline includes therapies for the treatment of glaucoma, as well as solid tumors, and acute myeloid leukemia (AML).
- Swiss start-up Oculis uses its solubilizing nanoparticle (SNP) technology to enhance drug solubility in the aqueous tear fluid. OCS-01, the startup’s lead candidate, is undergoing clinical trials for the treatment of diabetic macular edema (DME). Additionally, the startup’s pipeline includes topical treatments for post-cataract surgery inflammation, uveitis, and dry eye.
Market Competition
Key players in the market include pharmaceutical companies such as Novartis International AG, Pfizer Inc, Johnson & Johnson, Roche Holding AG, Bausch + Lomb, Allergan plc, and Alcon, Inc. along with the healthcare providers and technology companies among other global players.
- In May 2022 Santen Pharmaceutical received approval for Verkazia from the National Medical Products Administration (NMPA) in China through its legal entity for treating severe vernal keratoconjunctivitis (VKC) in children and adolescents aged four years and above.
- In March 2022, Visus Therapeutics Inc. announced the launch of the first of two pivotal phases 3 trials (BRIO-I and BRIO-II) for its lead asset, BRIMOCHOL PF, a topical preservative-free ophthalmic solution for treating presbyopia.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 500 million |
|
Market Value in 2033 |
US$ 814.45 million |
|
Growth Rate |
CAGR of 5% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Epidemic Keratoconjunctivitis Treatment Industry Survey
By Drug Class:
- Antihistamines
- Anti-Inflammatory
- Corticosteroids
By Route of Administration:
- Topical
- Oral
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
At what rate did the epidemic keratoconjunctivitis treatment market flourish from 2018 to 2022?
From 2018 to 2022, the Epidemic Keratoconjunctivitis Treatment Market grew at a CAGR of 4%.
What will be the growth rate of the global epidemic keratoconjunctivitis treatment market during the forecast period?
The global epidemic keratoconjunctivitis treatment market is expected to grow with a 5% CAGR during 2023 to 2033.
What will be the projected market size of the epidemic keratoconjunctivitis treatment market by 2033?
As of 2033, the epidemic keratoconjunctivitis treatment market is expected to reach US$ 814.45 million
Which end-user segment is expected to dominate the global epidemic keratoconjunctivitis treatment market during 2033?
According to the FMI analysis, hospital pharmacies account for the largest market share.
How is the North America Epidemic Keratoconjunctivitis Treatment Market projected to grow in 2033?
North America is expected to possess 40% market share for the Epidemic Keratoconjunctivitis Treatment Market.
How is the Asia Pacific Epidemic Keratoconjunctivitis Treatment Market projected to grow in 2033?
The Asia Pacific market is projected to increase significantly throughout the forecast period, with a share of 25% during the forecast period.
Table of Content
1. Executive Summary | Epidemic Keratoconjunctivitis Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Antihistamines 5.3.2. Anti-inflammatory 5.3.3. Corticosteroids 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Topical 6.3.2. Oral 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033 7.3.1. Hospital Pharmacy 7.3.2. Retail Pharmacy 7.3.3. Online Pharmacy 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. United States 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Class 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Class 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Class 15.2.3. By Route of Administration 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Class 16.1.2.2. By Route of Administration 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Class 16.2.2.2. By Route of Administration 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Class 16.3.2.2. By Route of Administration 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Class 16.4.2.2. By Route of Administration 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Class 16.5.2.2. By Route of Administration 16.5.2.3. By Distribution Channel 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Class 16.6.2.2. By Route of Administration 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Class 16.7.2.2. By Route of Administration 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Class 16.8.2.2. By Route of Administration 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Class 16.9.2.2. By Route of Administration 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Class 16.10.2.2. By Route of Administration 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Class 16.11.2.2. By Route of Administration 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Class 16.12.2.2. By Route of Administration 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Class 16.13.2.2. By Route of Administration 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Class 16.14.2.2. By Route of Administration 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Class 16.15.2.2. By Route of Administration 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Class 16.16.2.2. By Route of Administration 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Class 16.17.2.2. By Route of Administration 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Class 16.18.2.2. By Route of Administration 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Class 16.19.2.2. By Route of Administration 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Class 16.20.2.2. By Route of Administration 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Class 16.21.2.2. By Route of Administration 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Basilea Pharmaceutica and Stiefel Laboratories 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Regeneron 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Sanofi 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. LeoPharma 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Japan Tobacco Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Incyte Corporation 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Asana Biosciences 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. AbbVie Inc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Santen Pharmaceuticals Co. Ltd. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Jabs Biotech Pvt. Ltd. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 19: South Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 23: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 26: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 27: Oceania Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 30: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 31: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033 Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033 Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 82: South Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 83: South Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 91: South Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 92: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 97: South Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 98: South Asia Market Attractiveness by Route of Administration, 2023 to 2033 Figure 99: South Asia Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 101: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 102: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 103: East Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 111: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 112: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 117: East Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 118: East Asia Market Attractiveness by Route of Administration, 2023 to 2033 Figure 119: East Asia Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 121: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 122: Oceania Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 123: Oceania Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 131: Oceania Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 132: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 137: Oceania Market Attractiveness by Drug Class, 2023 to 2033 Figure 138: Oceania Market Attractiveness by Route of Administration, 2023 to 2033 Figure 139: Oceania Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 141: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 142: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 143: MEA Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 148: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 151: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 152: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 153: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 157: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 158: MEA Market Attractiveness by Route of Administration, 2023 to 2033 Figure 159: MEA Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
